Skip to main content

10.10.2017 | Onkologie | Onlineartikel

Immunotherapy: once more at the cutting edge of progress

Judith Moser
Approximately one third of patients with non–small-cell lung cancer (NSCLC) presents with stage III, locally advanced disease. For those with good performance status and unresectable tumours, the standard of care is platinum-based doublet chemotherapy with concurrent radiotherapy. Read more ...

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten